Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab plus concurrent chemoradiotherapy in elderly biliary tract cancer
ChiCTR2600130636Phase 2Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Aug 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adebrelimab in biliary cancer, intrahepatic cholangiocarcinoma (ICC), hilar cholangiocarcinoma (HC) and 1 more, sponsored by Jiangsu Provincial People's Hospital. Primary endpoints: Objective Response Rate (ORR) and Incidence and severity of adverse events (AEs). Planned start Aug 2026; status: not yet recruiting.
02
Drugs
adebrelimab
03
Conditions
biliary cancerintrahepatic cholangiocarcinoma (ICC)hilar cholangiocarcinoma (HC)gallbladder cancer
Beyond the preview
Go deeper on ChiCTR2600130636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600130636.